Eisai mulls NICE appeal after another no for Halaven
This article was originally published in Scrip
Executive Summary
Eisai is taking legal advice on whether it will appeal against negative final draft guidance from NICE, the health technology assessor for England and Wales, which rejects Halaven (eribulin), an end of life breast cancer drug. New economic modelling and an additional subgroup analysis failed to reassure NICE about its doubts over the drug's side effects and cost-effectiveness.